Obesity now affects over a billion adults and more children than those underweight, driving demand for GLP‑1 weight‑loss drugs originally created for Type 2 diabetes. In many markets these therapies cost up to $1,300 a month, limiting uptake to insured patients. China’s manufacturing heft promises to change that cost structure.

More than 60 GLP‑1 candidates are in late‑stage trials, with Chinese firms able to produce semaglutide at a fraction of current list prices. Pre‑publication research suggests a $3 injectable dose or $16 pill is feasible, undercutting Western pricing. Novo Nordisk has already paid $200 million for global rights to United Laboratories’ experimental drug, which showed a 20% weight loss in phase 2.

If Chinese makers capture the supply chain—from raw intermediates to finished pens—price erosion could arrive while the market expands to an estimated 30 million U.S. patients by 2030. Investors must reassess valuations that assume prolonged monopoly pricing, as the sector shifts toward volume‑driven margins.